Information on EC 3.4.21.21 - coagulation factor VIIa

for references in articles please use BRENDA:EC3.4.21.21
Word Map on EC 3.4.21.21
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:

The enzyme appears in viruses and cellular organisms

top print hide
EC NUMBER
COMMENTARY hide
3.4.21.21
-
top print hide
RECOMMENDED NAME
GeneOntology No.
coagulation factor VIIa
top print hide
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Selective cleavage of Arg-/-Ile bond in factor X to form factor Xa
show the reaction diagram
-
-
-
-
top print hide
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
-
-
endopeptidase
-
Phosphorylation
-
phosphorylation of signal transducers and activators of transcription
top
top print hide
CAS REGISTRY NUMBER
COMMENTARY hide
65312-43-8
-
top print hide
top print hide
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
physiological function
top print hide
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
4-methylumbelliferyl 4-guanidinobenzoate + H2O
?
show the reaction diagram
-
-
-
-
?
benzoyl-Ile-Glu-gamma-methoxyglutamyl-Gly-Arg-p-nitroanilide + H2O
benzoyl-Ile-Glu-gamma-methoxyglutamyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
i.e. S2222, 2% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
benzyloxycarbonyl-Arg-p-nitrobenzyl ester + H2O
benzyloxycarbonyl-Arg + 4-nitrophenyl
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-D-Arg-Gly-Arg + H2O
?
show the reaction diagram
-
i.e. S2765, 6% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
benzyloxycarbonyl-D-Arg-Gly-Arg-4-nitroanilide + H2O
?
show the reaction diagram
-
chromogenic S-2765
-
-
?
benzyloxycarbonyl-D-arginyl-D-glycyl-D-arginine-p-nitroanilide + H2O
p-nitroaniline + benzyloxycarbonyl-D-arginyl-D-glycyl-D-arginine
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-D-arginyl-glycyl-arginine-p-nitroanilide + H2O
benzyloxycarbonyl-D-arginyl-glycyl-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-D-arginyl-glycyl-L-arginyl-p-nitroanilide + H2O
benzyloxycarbonyl-D-arginyl-glycyl-L-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
chromozym t-PA + H2O
?
show the reaction diagram
-
-
-
-
?
D-cyclohexylglycyl-L-2-aminobutyryl-L-arginyl-4-nitroanilide + H2O
D-cyclohexylglycyl-L-2-aminobutyryl-L-arginine + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
D-Ile-Pro-Arg-4-nitroanilide + H2O
D-Ile-Pro-Arg + 4-nitroaniline
show the reaction diagram
D-Ile-Pro-Arg-p-nitroanilide + H2O
D-Ile-Pro-Arg + p-nitroaniline
show the reaction diagram
D-Ile-Pro-Arg-p-nitroanilide + H2O
p-nitroaniline + D-Ile-Pro-Arg
show the reaction diagram
-
-
-
-
?
D-isoleucyl-L-prolyl-L-arginine-p-nitroanilide + H2O
D-isoleucyl-L-prolyl-L-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
D-Phe-pipecolyl-Arg-p-nitroanilide + H2O
D-Phe-pipecolyl-Arg + p-nitroaniline
show the reaction diagram
D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide + H2O
D-phenylalanyl-L-pipecolyl-L-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
D-Pro-Phe-Arg-p-nitroanilide + H2O
D-Pro-Phe-Arg + p-nitroaniline
show the reaction diagram
-
i.e. S2302, 12% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
Eph tyrosine kinase receptor EphA2 + H2O
?
show the reaction diagram
-
cleavage site at the Arg159-His160 bond
-
-
?
Eph tyrosine kinase receptor EphB2 + H2O
?
show the reaction diagram
-
cleavage site at the Arg159-His160 bond
-
-
?
factor IX + H2O
?
show the reaction diagram
-
-
-
-
?
factor IX + H2O
activated factor IX
show the reaction diagram
-
-
-
-
?
factor IX + H2O
activated factor IX + ?
show the reaction diagram
-
-
-
-
?
factor IX + H2O
factor IXa + ?
show the reaction diagram
factor VIII + H2O
factor VIIIa + ?
show the reaction diagram
-
FVIII activity increases about 4-fold within 30 s in the presence of FVIIa/tissue factor. The heavy chain of FVIII is proteolyzed at Arg336. Arg740 and Arg372
-
-
?
factor X + H2O
?
show the reaction diagram
-
-
-
-
?
factor X + H2O
activated factor X
show the reaction diagram
-
-
-
-
?
factor X + H2O
activated factor X + ?
show the reaction diagram
factor X + H2O
factor Xa
show the reaction diagram
Factor X + H2O
Factor Xa + ?
show the reaction diagram
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide + H2O
H-D-isoleucyl-L-prolyl-arginine + p-nitroaniline
show the reaction diagram
-
i.e. S-2288
-
-
?
Ile-Pro-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
methanesulfonyl-D-CHA-Gly-Arg-4-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide + H2O
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
N-acetyl-Ala-P3-P2-Lys-7-amido-4-carbamoylmethylcoumarin + H2O
?
show the reaction diagram
-
P2: Val or Thr, P3: Gln, Arg, Asn or Pro
-
-
?
N-methoxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide + H2O
N-methoxycarbonyl-D-Nle-Gly-Arg + p-nitroaniline
show the reaction diagram
-
i.e. chromozym X, 11% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
N-methylsulfonyl-D-Phe-Gly-Arg-4-nitroanilide + H2O
N-methylsulfonyl-D-Phe-Gly-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
?
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide + H2O
N-methylsulfonyl-D-Phe-Gly-Arg + p-nitroaniline
show the reaction diagram
N-methylsulfonyl-D-phenyl-D-glycyl-D-arginyl-4-nitroanilide + H2O
N-methylsulfonyl-D-phenyl-D-glycyl-D-arginine + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
phosphoinositide + H2O
inositol phosphate + diacylglycerol
show the reaction diagram
-
-
-
-
?
protease-activated receptor 2 + H2O
?
show the reaction diagram
pyroGlu-Pro-Arg-p-nitroanilide + H2O
p-nitroaniline + pyroGlu-Pro-Arg
show the reaction diagram
-
-
-
-
?
pyroglutamyl-Gly-Arg-p-nitroanilide + H2O
pyroglutamyl-Gly-Arg + p-nitroaniline
show the reaction diagram
-
i.e. S2444, 2% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
pyroglutamyl-Phe-Lys-p-nitroanilide + H2O
pyroglutamyl-D-Phe-Gly-Arg + p-nitroaniline
show the reaction diagram
-
i.e. S2403, 1.4% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
pyroglutamyl-Pro-Arg-p-nitroanilide + H2O
pyroglutamyl-Pro-Arg + p-nitroaniline
show the reaction diagram
-
i.e. S2366, 38% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
S-2288 + H2O
?
show the reaction diagram
-
-
-
-
?
signal transducer and activator of transcription 5 + ?
activated signal transducer and activator of transcription 5 + ?
show the reaction diagram
-
STAT5
-
-
?
spectrozyme fVIIa + H2O
?
show the reaction diagram
-
-
-
-
?
spectrozyme Fxa + H2O
?
show the reaction diagram
-
chromogenic substrate
-
-
?
thrombinogen + H2O
thrombin + ?
show the reaction diagram
tissue factor + H2O
?
show the reaction diagram
-
-
-
-
?
Trp-Ala-Thr-Arg-7-amido-4-carbamoylmethylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
Z-D-arginyl-glycyl-arginine-p-nitroanilide + H2O
Z-D-arginyl-glycyl-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
additional information
?
-
top print hide
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
Eph tyrosine kinase receptor EphA2 + H2O
?
show the reaction diagram
-
cleavage site at the Arg159-His160 bond
-
-
?
Eph tyrosine kinase receptor EphB2 + H2O
?
show the reaction diagram
-
cleavage site at the Arg159-His160 bond
-
-
?
factor IX + H2O
?
show the reaction diagram
-
-
-
-
?
factor IX + H2O
factor IXa + ?
show the reaction diagram
factor VIII + H2O
factor VIIIa + ?
show the reaction diagram
-
FVIII activity increases about 4-fold within 30 s in the presence of FVIIa/tissue factor. The heavy chain of FVIII is proteolyzed at Arg336. Arg740 and Arg372
-
-
?
factor X + H2O
activated factor X + ?
show the reaction diagram
-
the enzyme initiates blood clotting after interacting with its cofactor tissue factor. The product of the reaction, activated factor X, is also the most efficient activator of zymogen factor VII
-
-
-
factor X + H2O
factor Xa
show the reaction diagram
-
-
-
-
?
Factor X + H2O
Factor Xa + ?
show the reaction diagram
protease-activated receptor 2 + H2O
?
show the reaction diagram
spectrozyme fVIIa + H2O
?
show the reaction diagram
-
-
-
-
?
thrombinogen + H2O
thrombin + ?
show the reaction diagram
tissue factor + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
top print hide
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
vitamin K
additional information
-
complex formation with the essential protein cofactor tissue factor
-
top print hide
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Mg2+
-
Mg2+ potentiates the activation of factor X and factor IX by factor VIIa
top print hide
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]methyl)propanedioic acid
-
-
2-(3'-amino-3-fluoro-4-(isopropylamino)-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
-
IC50: 340 nM
2-(3'-amino-4-(benzylamino)-3-fluoro-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
-
IC50: 500 nM
2-(3-allylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 700 nM
2-(3-benzylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 770 nM
2-(3-benzylsulfanyl-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0064 mM
2-(3-butylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0032 mM
2-([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]methyl)butanedioic acid
-
-
2-[3-(2-amino-ethylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0021 mM
2-[3-(3-amino-propylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 890 nM
2-[3-(4-amino-butylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 980 nM
2-[3-(4-tert-butyl-cyclohexylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.003 mM
2-[3-(adamantan-1-ylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.013 mM
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]butanedioic acid
-
-
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
2-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
2-[6-(3-acetylamino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.00161 mM
2-[6-(3-amino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 70 nM
2-[6-(3-amino-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 20 nM
2-[6-(3-amino-phenyl)-5-chloro-3-isopropylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 20 nM
2-[6-(3-bromo-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0042 mM
3-(3-[(R)-2-[(S)-1-(4-carbamimidoyl-benzylcarbamoyl)-3-carbamoylpropylcarbamoyl]-2-ethanesulfonylamino-ethyl]-1H-indol-5-yloxymethyl)-benzoic acid
-
-
3-amino-5-(1-(1-((4-(amino(imino)methyl)benzyl)-amino)-2-oxoethyl)-5-(isopropylamino)-6-oxo-1,6-dihydropyridin-2-yl)benzoic acid
-
IC50: 118 nM
3-amino-5-[1-[2-([4-[amino(imino)methyl]benzyl]amino)-2-oxoethyl]-3-chloro-5-(isopropylamino)-6-oxo-1,6-dihydropyrazin-2-yl]benzoic acid
-
pH 8.0, IC50: 16 nM, potent and highly selective inhibitor, selectivity versus factor Xa and thrombin
3-methyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
-
IC50: 300 nM, reversible, covalent
3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00145 mM, reversible, covalent
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid
-
pH 8.0, IC50: 360 nM
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid methyl ester
-
pH 8.0, IC50: 780 nM
3-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
3-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
4,4-dimethyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
-
IC50: 700 nM, reversible, covalent
4-aminobenzamidine
-
-
4-[5-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-1H-imidazol-4-yl]pyridine
-
-
5-(4-carboxybutoxy)-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
-
5-[(3-carboxybenzyl)oxy]-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
-
6-dimethylamino-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-hexanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
-
IC50: 0.00282 mM, reversible, covalent
acetyl-ALCDDPRVDRWYCQFVEG-NH2
-
i.e. E-76
active-site-inhibited factor Xa
-
80 nM: 60% inhibition
-
anti-gC antibody
-
20% inhibition
-
anti-TF antibody
-
40% inhibition
-
antithrombin
-
antithrombin III
-
benzamidine
-
-
benzamidine HCl
-
-
Bovine pancreatic trypsin inhibitor
-
mutant enzyme K192E is poorly inhibited, mutant enzyme K192Q is inhibited more than the wild-type enzyme
-
combination of the gC- and TF-specific antibodies
-
65% inhibition
-
D-Phe-Phe-Arg chloromethyl ketone
-
-
D-Phe-Phe-Arg methyl ketone
-
-
D-Phe-Phe-Arg-chloromethyl ketone
-
-
D-prolyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
-
-
diisopropylfluorophosphate
dimeric active site-inhibited blood clotting factor VIIa
-
dimeric fVIIai, 16000fold inhibitory effect
-
dimethyl (4-hydroxybenzyl)propanedioate
-
-
dimethyl 2-(4-hydroxybenzyl)butanedioate
-
-
dimethyl 2-(4-hydroxyphenyl)butanedioate
-
-
dimethyl 2-(4-hydroxyphenyl)pentanedioate
-
-
dimethyl 3-(4-hydroxyphenyl)pentanedioate
-
-
EEWEVLCWTWETCER
EEWEVLCWTWETCERGEG-(Z-domain of protein A)
-
IC50: 3.8 nM
-
EEWEVLCWTWETCERGEG-NH2
-
IC50: 1.5 nM
EEWEVLCWTWETCERGEGVEEELWEWR
-
maximal inhibition to 99%, IC50: 230 pM
-
EVLCWTWETCER-NH2
-
IC50: 470 nM
EWEVLCWTWETCERGE-(Z-domain of protein A)
-
IC50: 4.8 nM
-
FFR-FVIIa
-
derivate of FVIIa with a stably buried N-terminus representing the active conformation of FVIIa, IC50: 0.019 mM
-
hemextin A
-
0.05 mM, 70% inhibition
-
hemextin AB complex
-
IC50: 100 nM
-
MEEWEVLCWTWETCERGEGQ-(Z-domain of protein A)
-
IC50: 5.9 nM
-
N-(3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-6-oxo-5-phenethylamino-1,6-dihydro-pyrazin-2-yl]-phenyl)-2,2,2-trifluoro-acetamide
-
pH 8.0, IC50: 450 nM
N-(4-(amino(imino)methyl)benzyl)-2-(2,6-difluoro-3-((2-phenylethyl)amino)phenyl)acetamide
-
IC50: 0.0164 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-fluoro-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.00398 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.0027 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-(isopropylamino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.0025 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-methoxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.025 mM
N-(4-(amino(imino)methyl)benzyl)-2-(4-(isopropylamino)-3-methoxy-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.0147 mM
N-(4-(amino(imino)methyl)benzyl)-2-(5-(isopropylamino)-3,6-dioxo-2-phenylcyclohexa-1,4-dien-1-yl)acetamide
-
IC50: 0.0028 mM
N-(4-(amino(imino)methyl)benzyl)-2-(6-(3,5-diaminophenyl)-3-(isopropylamino)-2-oxopyridin-1(2H)-yl)acetamide
-
IC50: 52 nM
N-(4-carbamimidoyl-benzyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 340 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-m-tolyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.001 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-o-tolyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 430 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-p-tolyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.00414 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 630 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-phenylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0112 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-prop-2-ynylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 720 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-propylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 400 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-pyrrolidin-1-yl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0063 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclobutylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 400 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclohexylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0014 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-ethylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 400 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-isopropylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 200 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-methylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 700 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-ethyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.00345 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.00428 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(2-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0027 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(3-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0029 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(1-propyl-butylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0018 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-phenyl-propylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0126 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-trifluoromethyl-benzylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0063 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(4-phenyl-butylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0041 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1,1-dioxo-tetrahydro-16-thiophen-3-ylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.001 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0098 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 430 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 840 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-pentylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 900 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0038 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-dimethylamino-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0209 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-hydroxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 500 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-methoxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 880 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-morpholin-4-yl-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.008 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.006 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-dimethylamino-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0176 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-hydroxy-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 500 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-chloro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0043 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-hydroxy-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 600 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(6-hydroxy-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 470 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(isopropyl-methyl-amino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0091 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(2-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 340 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(3-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 200 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.003 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0018 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0016 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.00198 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-dimethylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0012 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0023 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methanesulfonylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 600 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0052 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 600 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-nitro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.00252 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.00888 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0081 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.02345 mM
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-2-oxo-6-phenyl-3-[2-(3-trifluoromethyl-phenyl)-ethylamino]-2H-pyrazin-1-yl}-acetamide
-
pH 8.0, IC50: 0.03 mM
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(3-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
-
pH 8.0, IC50: 180 nM
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(4-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
-
pH 8.0, IC50: 600 nM
N-(5-carbamimidoyl-pyridin-2-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0167 mM
N-(6-carbamimidoyl-pyridin-3-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0014 mM
N-(ethylsulfonyl)-1-methyl-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
-
N-(ethylsulfonyl)-5-hydroxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
-
N-(ethylsulfonyl)-5-methoxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
-
N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-L-glutamamide
-
-
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3,4,5-trifluoro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 200 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3-trifluoromethyl-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 800 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-iodo-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00156 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-nitro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00588 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-hydroxy-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 110 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-m-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 170 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-1-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0056 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-2-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00195 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-o-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 240 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-p-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00129 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-phenyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 42 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-pyridin-3-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 200 nM, reversible, covalent
N-[2-(1-benzyl-1H-imidazol-4-yl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00997 mM, reversible, covalent
N-[2-(2,6-dimethyl-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 700 nM, reversible, covalent
N-[2-(2-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 90 nM, reversible, covalent
N-[2-(3,4-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 160 nM, reversible, covalent
N-[2-(3,5-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 190 nM, reversible, covalent
N-[2-(3-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 230 nM, reversible, covalent
N-[2-(3-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 200 nM, reversible, covalent
N-[2-(4-acetylamino-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 570 nM, reversible, covalent
N-[2-(4-bromo-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 760 nM, reversible, covalent
N-[2-(4-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 680 mM, reversible, covalent
N-[2-(4-cyano-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 340 nM, reversible, covalent
N-[2-(4-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 170 nM, reversible, covalent
N-[2-benzo[b]thiophen-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0005 mM, reversible, covalent
N-[2-benzyloxy-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00153 mM, reversible, covalent
N-[2-biphenyl-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00183 mM, reversible, covalent
N-[2-biphenyl-4-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0178 mM, reversible, covalent
N-[2-cyclohexyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0033 mM, reversible, covalent
N-[2-cyclopropyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 820 nM, reversible, covalent
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamic acid cyclohexyl ester
-
IC50: 0.00318 mM, reversible, covalent
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-methanesulfonyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
-
IC50: 0.0137 mM, reversible, covalent
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-phenyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
-
IC50: 900 nM, reversible, covalent
N1-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamide
-
IC50: 0.00103 mM, reversible, covalent
p-aminobenzamidine
-
-
R-4-[2-(3-aminobenzenesulfonylamino)-1-(3,5-diethoxy-2-fluorophenyl)-2-oxoethylamino]-2-hydroxy-benzamidine
-
incubation with enzyme in 100 mM Hepes, pH 7.8, 140 mM NaCl, 0.1% (v/v) polyethylene glycol 8000, 0.02% (v/v) Tween 80, 5 mM CaCl2 for 40 min at room temperature
SAEWEVLCWTWEGCGSVGL-(Z-domain of protein A)
-
IC50: 4400 nM
SEEWEVLCWTWEDCRLEGLE-(Z-domain of protein A)
-
IC50: 93 nM
-
tissue factor pathway inhibitor
-
Trp-Tyr-Thr-Arg-chloromethyl ketone
-
-
V154G-FVIIa
-
derivate of FVIIa with a fully exposed N-terminus representing the zymogen-like conformation of FVIIa, IC50: 0.014 mM
-
VLCWTWETCER-NH2
-
IC50: 0.022 nM
WEVLCWTWETC-NH2
-
IC50: 0.013 mM
WEVLCWTWETCE-NH2
-
IC50: 0.007 mM
WEVLCWTWETCER-NH2
-
IC50: 2.5 nM
Zn2+
-
two Zn2+ bind with high affinity to factor VIIa outside the N-terminal gamma-carboxyglutamic acid domain. Binding of Zn2+ is influenced by presence of Ca2+ and results in decreased amidolytic activity and slightly reduced affinity for tissue factor. After binding to tissue factor, factor VIIa is less susceptible to zinc inhibition
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]acetic acid
-
-
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
top print hide
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
factor Xa
-
Herpes simplex virus 1 encoded glycoprotein C
-
gC, 1000fold activity-enhancing effect in the absence of tissue factor and in the presence of 5 mM Ca2+ and 0.1 mM synthetic small unilamellar vesicles composed of 75% phosphatidylcholine and 25% phosphatidylserine
-
Janus kinase 2
-
-
-
phospholipid vesicle
-
oleoyl-1,2-diacyl-sn-glycero-3-phosphocholine and dioleoyl-1,2-diacyl-sn-glycero-3-(phospho-L-serine)
-
protease-activated receptor-2
-
1.5fold activity enhancement
-
tissue factor
-
tissue factor TF
-
TF-induced allosteric activation of FVIIa, binding structure, overview
-
vitamin K
additional information
-
top print hide
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.19
benzyloxycarbonyl-Arg-p-nitrobenzyl ester
-
-
1.8 - 14
D-Ile-Pro-Arg-4-nitroanilide
0.85 - 10.4
D-Ile-Pro-Arg-p-nitroanilide
0.000012 - 68
Factor X
-
1.5 - 9.8
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
0.67
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide
-
wild-type enzyme
0.8 - 50
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
11.8
S-2288
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 37°C
0.67
spectrozyme fVIIa
-
wild-type enzyme
additional information
additional information
-
top print hide
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1.8
benzyloxycarbonyl-Arg-p-nitrobenzyl ester
-
-
0.59 - 44.2
D-Ile-Pro-Arg-p-nitroanilide
0.000007 - 6800
Factor X
-
17
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide
-
wild-type enzyme
8.4 - 396000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
13
S-2288
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 37°C
16 - 17
spectrozyme fVIIa
additional information
additional information
-
top print hide
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0012 - 270
Factor X
-
top print hide
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000021
([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]methyl)propanedioic acid
-
-
0.000004
2-([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]methyl)butanedioic acid
-
-
0.000004
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]butanedioic acid
-
-
0.000022
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
0.000017
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
0.000001
2-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
0.000036
3-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
0.000013
3-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
0.1 - 3.2
4-aminobenzamidine
0.0000002
EEWEVLCWTWETCER
-
inhibition of amidolytic activity
0.038 - 1.41
p-aminobenzamidine
0.00000035
R-4-[2-(3-aminobenzenesulfonylamino)-1-(3,5-diethoxy-2-fluorophenyl)-2-oxoethylamino]-2-hydroxy-benzamidine
-
-
0.000002
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]acetic acid
-
-
0.000015
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
0.000003
[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
additional information
additional information
-
top print hide
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00034
2-(3'-amino-3-fluoro-4-(isopropylamino)-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
Homo sapiens
-
IC50: 340 nM
0.0005
2-(3'-amino-4-(benzylamino)-3-fluoro-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
Homo sapiens
-
IC50: 500 nM
0.0007
2-(3-allylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 700 nM
0.00077
2-(3-benzylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 770 nM
0.0064
2-(3-benzylsulfanyl-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0064 mM
0.0032
2-(3-butylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0032 mM
0.0021
2-[3-(2-amino-ethylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0021 mM
0.00089
2-[3-(3-amino-propylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 890 nM
0.00098
2-[3-(4-amino-butylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 980 nM
0.003
2-[3-(4-tert-butyl-cyclohexylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.003 mM
0.013
2-[3-(adamantan-1-ylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.013 mM
0.00161
2-[6-(3-acetylamino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00161 mM
0.00007
2-[6-(3-amino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 70 nM
0.00002
2-[6-(3-amino-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 20 nM
0.00002
2-[6-(3-amino-phenyl)-5-chloro-3-isopropylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 20 nM
0.0042
2-[6-(3-bromo-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0042 mM
0.000039
3-(3-[(R)-2-[(S)-1-(4-carbamimidoyl-benzylcarbamoyl)-3-carbamoylpropylcarbamoyl]-2-ethanesulfonylamino-ethyl]-1H-indol-5-yloxymethyl)-benzoic acid
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000118
3-amino-5-(1-(1-((4-(amino(imino)methyl)benzyl)-amino)-2-oxoethyl)-5-(isopropylamino)-6-oxo-1,6-dihydropyridin-2-yl)benzoic acid
Homo sapiens
-
IC50: 118 nM
0.000016
3-amino-5-[1-[2-([4-[amino(imino)methyl]benzyl]amino)-2-oxoethyl]-3-chloro-5-(isopropylamino)-6-oxo-1,6-dihydropyrazin-2-yl]benzoic acid
Homo sapiens
-
pH 8.0, IC50: 16 nM, potent and highly selective inhibitor, selectivity versus factor Xa and thrombin
0.0003
3-methyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
Homo sapiens
-
IC50: 300 nM, reversible, covalent
0.00145
3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00145 mM, reversible, covalent
0.00036
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid
Homo sapiens
-
pH 8.0, IC50: 360 nM
0.00078
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid methyl ester
Homo sapiens
-
pH 8.0, IC50: 780 nM
0.0007
4,4-dimethyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
Homo sapiens
-
IC50: 700 nM, reversible, covalent
0.000204
5-(4-carboxybutoxy)-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000056
5-[(3-carboxybenzyl)oxy]-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.00282
6-dimethylamino-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-hexanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
Homo sapiens
-
IC50: 0.00282 mM, reversible, covalent
0.0024
D-prolyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.0000015 - 0.0000016
EEWEVLCWTWETCER
0.0000038
EEWEVLCWTWETCERGEG-(Z-domain of protein A)
Homo sapiens
-
IC50: 3.8 nM
-
0.0000015
EEWEVLCWTWETCERGEG-NH2
Homo sapiens
-
IC50: 1.5 nM
0.00000023
EEWEVLCWTWETCERGEGVEEELWEWR
Homo sapiens
-
maximal inhibition to 99%, IC50: 230 pM
-
0.00047
EVLCWTWETCER-NH2
Homo sapiens
-
IC50: 470 nM
0.0000048
EWEVLCWTWETCERGE-(Z-domain of protein A)
Homo sapiens
-
IC50: 4.8 nM
-
0.019
FFR-FVIIa
Homo sapiens
-
derivate of FVIIa with a stably buried N-terminus representing the active conformation of FVIIa, IC50: 0.019 mM
-
0.0001
hemextin AB complex
Homo sapiens
-
IC50: 100 nM
-
0.0000059
MEEWEVLCWTWETCERGEGQ-(Z-domain of protein A)
Homo sapiens
-
IC50: 5.9 nM
-
0.00045
N-(3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-6-oxo-5-phenethylamino-1,6-dihydro-pyrazin-2-yl]-phenyl)-2,2,2-trifluoro-acetamide
Homo sapiens
-
pH 8.0, IC50: 450 nM
0.0164
N-(4-(amino(imino)methyl)benzyl)-2-(2,6-difluoro-3-((2-phenylethyl)amino)phenyl)acetamide
Homo sapiens
-
IC50: 0.0164 mM
0.00398
N-(4-(amino(imino)methyl)benzyl)-2-(3-fluoro-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.00398 mM
0.0027
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.0027 mM
0.0025
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-(isopropylamino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.0025 mM
0.025
N-(4-(amino(imino)methyl)benzyl)-2-(3-methoxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.025 mM
0.0147
N-(4-(amino(imino)methyl)benzyl)-2-(4-(isopropylamino)-3-methoxy-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.0147 mM
0.0028
N-(4-(amino(imino)methyl)benzyl)-2-(5-(isopropylamino)-3,6-dioxo-2-phenylcyclohexa-1,4-dien-1-yl)acetamide
Homo sapiens
-
IC50: 0.0028 mM
0.000052
N-(4-(amino(imino)methyl)benzyl)-2-(6-(3,5-diaminophenyl)-3-(isopropylamino)-2-oxopyridin-1(2H)-yl)acetamide
Homo sapiens
-
IC50: 52 nM
0.00034
N-(4-carbamimidoyl-benzyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 340 nM
0.001
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-m-tolyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.001 mM
0.00043
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-o-tolyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 430 nM
0.00414
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-p-tolyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00414 mM
0.00063
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 630 nM
0.0112
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-phenylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0112 mM
0.00072
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-prop-2-ynylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 720 nM
0.0004
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-propylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 400 nM
0.0063
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-pyrrolidin-1-yl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0063 mM
0.0004
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclobutylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 400 nM
0.0014
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclohexylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0014 mM
0.0004
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-ethylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 400 nM
0.0002
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-isopropylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 200 nM
0.0007
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-methylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 700 nM
0.00345
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-ethyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00345 mM
0.00428
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00428 mM
0.0027
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(2-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0027 mM
0.0029
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(3-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0029 mM
0.0018
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(1-propyl-butylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0018 mM
0.0126
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-phenyl-propylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0126 mM
0.0063
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-trifluoromethyl-benzylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0063 mM
0.0041
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(4-phenyl-butylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0041 mM
0.001
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1,1-dioxo-tetrahydro-16-thiophen-3-ylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.001 mM
0.0098
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0098 mM
0.00043
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 430 nM
0.00084
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 840 nM
0.0009
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-pentylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 900 nM
0.0038
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0038 mM
0.0209
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-dimethylamino-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0209 mM
500
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-hydroxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 500 mM
880
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-methoxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 880 mM
0.008
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-morpholin-4-yl-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.008 mM
0.006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.006 mM
0.0176
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-dimethylamino-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0176 mM
0.0005
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-hydroxy-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 500 nM
0.0043
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-chloro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0043 mM
0.0006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-hydroxy-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.00047
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(6-hydroxy-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 470 nM
0.0091
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(isopropyl-methyl-amino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0091 mM
0.00034
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(2-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 340 nM
0.0002
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(3-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 200 nM
0.003
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.003 mM
0.0018
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0018 mM
0.0016
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0016 mM
0.00198
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00198 mM
0.0012
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-dimethylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0012 mM
0.0023
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0023 mM
0.0006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methanesulfonylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.0052
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0052 mM
0.0006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.00252
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-nitro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00252 mM
0.00888
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00888 mM
0.0081
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0081 mM
0.02345
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.02345 mM
0.03
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-2-oxo-6-phenyl-3-[2-(3-trifluoromethyl-phenyl)-ethylamino]-2H-pyrazin-1-yl}-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.03 mM
0.00018
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(3-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
Homo sapiens
-
pH 8.0, IC50: 180 nM
0.0006
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(4-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.0167
N-(5-carbamimidoyl-pyridin-2-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0167 mM
0.0014
N-(6-carbamimidoyl-pyridin-3-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0014 mM
0.000069
N-(ethylsulfonyl)-1-methyl-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.00014
N-(ethylsulfonyl)-5-hydroxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000065
N-(ethylsulfonyl)-5-methoxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000062
N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-L-glutamamide
Homo sapiens
-
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.0002
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3,4,5-trifluoro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 200 nM, reversible, covalent
0.0008
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3-trifluoromethyl-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 800 nM, reversible, covalent
0.00156
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-iodo-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00156 mM, reversible, covalent
0.00588
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-nitro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00588 mM, reversible, covalent
0.00011
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-hydroxy-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 110 nM, reversible, covalent
0.00017
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-m-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 170 nM, reversible, covalent
0.0056
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-1-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0056 mM, reversible, covalent
0.00195
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-2-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00195 mM, reversible, covalent
0.00024
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-o-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 240 nM, reversible, covalent
0.00129
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-p-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00129 mM, reversible, covalent
0.000042
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-phenyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 42 nM, reversible, covalent
0.0002
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-pyridin-3-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 200 nM, reversible, covalent
0.00997
N-[2-(1-benzyl-1H-imidazol-4-yl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00997 mM, reversible, covalent
0.0007
N-[2-(2,6-dimethyl-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 700 nM, reversible, covalent
0.00009
N-[2-(2-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 90 nM, reversible, covalent
0.00016
N-[2-(3,4-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 160 nM, reversible, covalent
0.00019
N-[2-(3,5-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 190 nM, reversible, covalent
0.00023
N-[2-(3-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 230 nM, reversible, covalent
0.0002
N-[2-(3-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 200 nM, reversible, covalent
0.00057
N-[2-(4-acetylamino-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 570 nM, reversible, covalent
0.00076
N-[2-(4-bromo-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 760 nM, reversible, covalent
680
N-[2-(4-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 680 mM, reversible, covalent
0.00034
N-[2-(4-cyano-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 340 nM, reversible, covalent
0.00017
N-[2-(4-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 170 nM, reversible, covalent
0.0005
N-[2-benzo[b]thiophen-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0005 mM, reversible, covalent
0.00153
N-[2-benzyloxy-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00153 mM, reversible, covalent
0.00183
N-[2-biphenyl-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00183 mM, reversible, covalent
0.0178
N-[2-biphenyl-4-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0178 mM, reversible, covalent
0.0033
N-[2-cyclohexyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0033 mM, reversible, covalent
0.00082
N-[2-cyclopropyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 820 nM, reversible, covalent
0.00318
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamic acid cyclohexyl ester
Homo sapiens
-
IC50: 0.00318 mM, reversible, covalent
0.0137
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-methanesulfonyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
Homo sapiens
-
IC50: 0.0137 mM, reversible, covalent
0.0009
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-phenyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
Homo sapiens
-
IC50: 900 nM, reversible, covalent
0.00103
N1-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamide
Homo sapiens
-
IC50: 0.00103 mM, reversible, covalent
0.0044
SAEWEVLCWTWEGCGSVGL-(Z-domain of protein A)
Homo sapiens
-
IC50: 4400 nM
0.000093
SEEWEVLCWTWEDCRLEGLE-(Z-domain of protein A)
Homo sapiens
-
IC50: 93 nM
-
0.014
V154G-FVIIa
Homo sapiens
-
derivate of FVIIa with a fully exposed N-terminus representing the zymogen-like conformation of FVIIa, IC50: 0.014 mM
-
0.000000022
VLCWTWETCER-NH2
Homo sapiens
-
IC50: 0.022 nM
0.013
WEVLCWTWETC-NH2
Homo sapiens
-
IC50: 0.013 mM
0.007
WEVLCWTWETCE-NH2
Homo sapiens
-
IC50: 0.007 mM
0.0000025
WEVLCWTWETCER-NH2
Homo sapiens
-
IC50: 2.5 nM
top print hide
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
top print hide
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.4
-
assay at
top print hide
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
15
-
cleavage of Ile-Pro-Arg-p-nitroanilide
22
-
assay at room temperature
30
-
cleavage of Ile-Pro-Arg-p-nitroanilide, in presence of tissue factor
37
-
assay at
top print hide
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 40
-
5°C: about 90% of maximal activity, 40°C: about 50% of maximal activity, cleavage of Ile-Pro-Arg-p-nitroanilide
top print hide
top print hide
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
top print hide
PDB
SCOP
CATH
ORGANISM
UNIPROT
top print hide
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
45530
-
fully de-N-glycosylated protein, studied by MALDI-TOF mass spectrometry
46070
-
calculated from the amino acid sequence and considering 12 disulfide bridges
50100
-
native FVIIa, studied by MALDI-TOF mass spectrometry
55000
-
SDS-PAGE, recombinant fusion protein
additional information
-
the zymogen, factor VII, is composed of a single polypeptide chain polypeptide of 48000 Da, with the NH2-terminal sequence Ala-Asn-Ala-Phe-Leu-(gamma-carboxyglutamic acid)-(gamma-carboxyglutamic acid)-Leu-Arg-Pro. It is converted to a two-chain form, factor VIIa, connected by disulfide bonds by the action of factor Xa, in the presence of phospholipids and calcium and by factor XIIa, without additional cofactors
top print hide
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
top print hide
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
proteolytic modification
additional information
-
FVII undergoes many posttranslational modifications such as gamma-carboxylation, N- and O-glycosylation, beta-hydroxylation
top print hide
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
2 A resolution crystal structure of a zymogen form of factor VII comprising the EGF2 and protease domains is revealed in a complex with the exosite binding inhibitory peptide A-183 and a vacant active site, hanging-drop method
-
crystal structure at 2.0 A resolution of active-site-inhibited factor VIIa complexed with the cleaved extracellular domain of tissue factor
-
crystal structure of factor FVIIa is inhibited at the active site with 1,5-dansyl-Glu-Gly-Arg-chloromethyl ketone and lacking the Gla domain
-
enzyme complexed with acetyl-ALCDDPRVDRWYCQFVEG-NH2, hanging-drop method
-
hanging drop vapour diffusion method
-
N-terminally truncated factor VII, activated recombinant factor VII is crystallized in the presence of the reversible S1-site inhibitor benzamidine
-
purified complex between Trp-Tyr-Thr-Arg-cmk-FVIIa and sTF1?209, hanging drop vapour diffusion method, 10 mg/ml protein in 10 mM Tris-HCl, pH 7.5, 100 mM NaCl and 2 mM CaCl2, with 0.1 M sodium citrate, 16.5–15.5% w/v PEG 4000 and 12% v/v propan-1-ol, pH 5.6, as the precipitating agent, X-ray diffraction structure determination and analysis, modeling
-
sitting-drop vapour-diffusion method
-
structure of the gamma-carboxyglutamic acid-domainless human coagulation factor VIIa at a resolution of 2.8 A
-
top print hide
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
58
-
heat inactivation is fully reversible up to 15 min
60
-
the melting temperature of the recombinant enzyme is at about 60°C. GlycoPEGylation delays the thermally induced aggregation, and slightly increases the unfolding temperature of the protein from 57.7°C to 59°C
top print hide
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
anion exchange chromatography
-
dialysis
-
factor VII
method not mentioned
-
purification process starts with pH adjustment of the clarified medium, which is loaded onto an anion-exchange column. Detergent is added to the eluate in order to inactivate enveloped viruses. Subsequently, FVII and FVIIa are affinity purified on a column with a monoclonal antibody recognizing the FVII Gla domain in its functional conformation. Only FVII/FVIIa without propetide and with a functional and sufficiently gamma-carboxylated Gla domain is captured and purified. The eluate from the affinity column is subjected to two anion-exchange chromatography steps
-
recombinant factor VII
-
recombinant FVII zymogen from BHK cell medium
-
using Ni-NTA chromatography
-
wild-type and mutant enzymes expressed in CHO-K1 cells
-
top print hide
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expressed as a recombinant protein
-
expressed in baby hamster kidney cells
-
expressed in CHO-K1 cells
-
expressed in human 293 cells
-
expressed in Spodoptera frugiperda Sf9 cell line using the baculovirus expression system. Recombinant human FVII (rhFVII) produced in this study carries a 6x-His tag at the C-terminal
-
expression of an N-terminally truncated factor VII in Escherichia coli
-
expression of wild-type and mutant enzymes in BHK cells
-
expression of wild-type and mutant enzymes in CHO-K1 cells
-
for expression as a recombinant protein in baby hamster kidney cells cDNA comprising the entire FVII open reading frame encoding signal peptide, propeptide and the mature FVII protein is inserted into an expression plasmid containing the elements required to direct transcription of the FVII cDNA in mammalian cells. The endogenous signal peptide and propeptide of FVII are necessary for intracellular transport and processing of FVII in the producer cells but are both removed prior to secretion
-
genetic localization at 13q34, cloning from a liver gene library, expression in BHK cells with secretion to the medium
-
recombinant wild-type and mutant factor VII is expressed in Chinese hamster ovary cells
-
top print hide
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
raised FVIIc activity levels in coronary heart disease are significantly positively correlated with insulin resistance
-
seven days of a partial sleep deprivation in a mouse model reduces significantly factor VII mRNA expression
-
top print hide
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
306X
-
mutation studies show that the interaction between protein cofactor tissue factor and methionine-306 in the serine protease domain of FVIIa triggers the activation process and suggested some ensuing steps on the pathway to the active conformation
A294V
-
mutant enzyme shows delayed activation by activated factor X as well as reduced activity towards peptidyl and macromolecular substrates without impairing the catalytic efficiency of the triad
C164V/V299C-FVIIa
-
introduction of a new disulfide bridge between Cys-159 and an introduced Cys at position 299
D102Q
-
inactive mutant enzyme
D186A
-
turnover-number for activation of factor X is 5.5fold lower than that of the wild-type factor VII, Km-value for activation of factor X is 1.2fold lower than that of the wild-type factor VII
D343H
-
mutant enzyme shows no activity with methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide, factor X and factor IX
D72N
-
the mutant shows 13% of wild type FVIIa signaling activity towards protease-activated receptor 2
DELTA360-329
-
lower affinity for soluble tissue factor as compared to wild-type factor VIIa, 7fold smaller tissue factor-mediated acceleration of amidolytic activity compared to wild type factor VIIa
E154A
-
slightly increased Km-value and decreased turnover number compared to the wild-type enzyme
E154R
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
E296R
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
F256A
-
turnover-number and Km-value for activation of factor X are nearly identical to that of the wild-type factor VII
F374P
-
the specific clotting activity in presence of tissue factor is 50% of that of the wild-type factor VIIa
G372A
-
mutant G372A, both in the free and tissue factor-bound form, exhibit reduced cleavage of factor X and of D-Ile-Pro-Arg-4-nitroanilide (kcat increased compared to wild-type), and have increased Km values compared with wild-type FVIIa. Inhibition of mutant G372A +soluble tissue factor by 4-aminobenzamidine is characterized by a seven-fold higher Ki than obtained with wild-type. Crystallographic and modelling data suggest that the most active conformation of FVIIa depends on the backbone hydrogen bond between Gly372 and Arg315 in the 170 loop. Native and active site-inhibited mutant G372A binds soluble tissue factor with the same affinity as the corresponding forms of FVIIa
H101A
-
turnover-number for activation of factor X is 1.12fold lower than that of the wild-type factor VII, Km-value for activation of factor X is 1.23fold lower than that of the wild-type factor VII. Activation by factor Xa is significantly more slowly than that of wild-type enzyme. Tissue factor affinity and small substrate activity is similar to wild-type enzyme
H216A
-
mutant enzyme with decreased sensitivity to Zn2+ inhibition
H257A
-
mutant enzyme with decreased sensitivity to Zn2+ inhibition
K192E
-
completely ineffective mutant enzyme
K305V
-
the ratio of turnover number to Km-value is 5.3fold higher than that of the wild-type enzyme with factor X as substrate, increased inhibition rate compared to wild-type enzyme with antithrobin in presence of heparin
K341Q
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
L144A/R147A/D186A
-
turnover-number for activation of factor X is 239fold lower than that of the wild-type factor VII, Km-value for activation of factor X is 1.2fold higher than that of the wild-type factor VII
L280I/V299M-FVIIa
-
without description
L305V
-
mutant enzyme exhibits an increased rate of inhibition as compared with wild-type enzyme, both by D-Phe-Phe-Arg-chloromethyl ketone and antithombin III in presence of heparin. In complex with tissue factor both the amydolytic activity and the proteolytic activity are similar to that of the wild-type activity.The specific clotting activity in presence of tissue factor is 93% of that of the wild-type factor VIIa
L305V/K337A
-
the ratio of turnover number to Km-value is 6.3fold higher than that of the wild-type enzyme with factor X as substrate, increased inhibition rate compared to wild-type enzyme with antithrobin in presence of heparin
L305V/M306D/D309S
-
amidylatic and proteolytic activity are virtually unaffected by the presence of tissue factor, 1.1fold increase. The specific clotting activity in presence of tissue factor is about 1% of that of the wild-type factor VIIa
M156K
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
M298K
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
M306N
-
amidolytic activity of the mutant enzyme is stimulated 7fold
M306N/N309S
-
amidolytic activity of the mutant enzyme is stimulated 1.5fold
M306S
-
amidolytic activity of the mutant enzyme is stimulated 9fold
M306T
-
amidolytic activity of the mutant enzyme is stimulated 12fold
N100A
-
turnover-number for activation of factor X is 3fold lower than that of the wild-type factor VII, Km-value for activation of factor X is 1.4fold lower than that of the wild-type factor VII
N100A/H101A/Y179A/F256A
-
turnover-number for activation of factor X is 3fold lower than that of the wild-type factor VII, Km-value for activation of factor X is nearly identical to that of the wild-type factor VII. Activation by factor Xa is significantly more slowly than that of wild-type enzyme
P10Q
-
site-directed mutagenesis, the mutant shows 2fold enhancement in membrane binding affinity over wild-type FVIIa
P10Q/K32E
-
site-directed mutagenesis, the mutant shows 27fold enhancement in membrane binding affinity over wild-type FVIIa, the double mutant displays a significantly improved procoagulant effect in haemophilic blood
P10Q/K32E/D33F/A34E
-
site-directed mutagenesis, the mutant shows 150-300fold enhancement in membrane binding affinity over wild-type FVIIa
P10Q/Q32E
-
mutant enzyme with elevated affinity for membrane. Phospholipid and cell-based assays show that mutant enzyme has an up to 40fold higher function then wild-type enzyme in both tissue-factor dependent reaction and in tissue factor independent reaction
Q143N
-
the mutant reduces interleukin-8 expression to background levels but maintains essentially normal pro-coagulant activity
Q143R
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
Q176G
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
Q217E
-
the mutant shows enhanced protease-activated receptor 2 activation
Q286R
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
Q40A
-
the mutant reduces interleukin-8 expression to background levels but maintains essentially normal pro-coagulant activity
Q40G
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
R147A
-
turnover-number for activation of factor X is 3.7fold lower than that of the wild-type factor VII, Km-value for activation of factor X is 1.2fold lower than that of the wild-type factor VII
R152Q
-
mutant enzyme shows no activity with methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide, factor X and factor IX
R353Q
-
in an observational study of 93 Japanese women 10 SNPs in relation to thrombosis or atherosclerosis are studied. Factor VII Arg353Gln and higher HDL-cholesterol (HDL-C) are linked to Arg/Arg carriers at higher levels
S344A
-
mutant enzyme shows no activity with methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide, factor X and factor IX
T151A
-
the mutant shows 13% of wild type FVIIa signaling activity towards protease-activated receptor 2
T151Q
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
T151S
-
the variant activates macromolecular coagulation substrates and supports signaling of the ternary tissue factor-FVIIa-Xa complex normally but is severely impaired in binary tissue factor-FVIIa-protease-activated receptor 2 signaling
T239A
-
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
T239G
-
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
T239I
-
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
T239Y
-
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
T293Q
-
site-directed mutagenesis, activity and active site structure in comparison to the wild-type
T99A